Oruka Competitors

Stocks . USA . 
Stock . Oruka Therapeutics
ORKA Stock   34.30  0.07  0.20%   
Oruka Therapeutics competes with Phathom Pharmaceuticals, BridgeBio Oncology, Rapport Therapeutics, Kodiak Sciences, and Xencor; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Oruka Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Oruka Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Oruka Therapeutics Correlation with its peers.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.

Oruka Therapeutics vs Mind Medicine Correlation

Significant diversification

The correlation between Oruka Therapeutics and MNMD is 0.09 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Oruka Therapeutics and MNMD in the same portfolio, assuming nothing else is changed.

Moving against Oruka Stock

  0.41TRV The Travelers CompaniesPairCorr
  0.36JPM JPMorgan ChasePairCorr
  0.34PTAIF PT Astra InternationalPairCorr
  0.32BKRKF PT Bank RakyatPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
30.3934.3038.21
Details
Intrinsic
Valuation
LowRealHigh
28.7232.6336.54
Details
Naive
Forecast
LowNextHigh
30.7634.6738.58
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
25.6231.6537.69
Details

Oruka Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Oruka Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Oruka and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Oruka Therapeutics does not affect the price movement of the other competitor.

High positive correlations

NRIX
+ 0.89
KOD
RAPP
+ 0.69
PHAT
URGN
+ 0.68
XNCR
NRIX
+ 0.65
RAPP
ANAB
+ 0.64
KOD
ANAB
+ 0.63
RAPP
  

High negative correlations

MNMD
- 0.7
XNCR
OCS
- 0.68
URGN
OCS
- 0.68
XNCR
MNMD
- 0.63
RAPP
MNMD
- 0.62
NRIX
MNMD
- 0.5
PHAT

Risk-Adjusted Indicators

There is a big difference between Oruka Stock performing well and Oruka Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Oruka Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PHAT  2.74  0.08  0.01  0.54  3.68 
(2.83)
 5.99 
(4.86)
 24.16 
BBOT  3.41  0.09  0.01 (1.18) 3.65 
(4.26)
 8.45 
(6.24)
 27.79 
RAPP  2.72  0.11  0.02  0.75  3.58 
(2.56)
 5.18 
(6.01)
 15.66 
KOD  4.17  0.40  0.09  0.33  4.44 
(4.49)
 10.04 
(6.94)
 25.07 
XNCR  2.77 (0.22) 0.00  0.47  0.00 
 0.00 
 6.33 
(5.08)
 16.84 
NRIX  3.20  0.62  0.17  1.90  3.09 
(3.81)
 9.23 
(5.37)
 27.63 
ANAB  2.72  0.72  0.15 (0.85) 3.70 
(2.96)
 6.44 
(5.26)
 20.41 
URGN  3.24  0.06  0.00  0.52  4.07 
(3.76)
 6.25 
(5.50)
 36.24 
OCS  1.82  0.69  0.32  3.05  1.30 
(2.06)
 5.79 
(2.58)
 15.08 
MNMD  2.74  0.00  0.17  0.00  2.54 
(3.32)
 6.21 
(4.21)
 15.87 

Oruka Therapeutics Competitive Analysis

The better you understand Oruka Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Oruka Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Oruka Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ORKA PHAT BBOT RAPP KOD XNCR NRIX ANAB URGN OCS
 0.20 
 34.30 
Oruka
 1.02 
 13.81 
Phathom
 2.65 
 12.03 
BridgeBio
 4.28 
 27.75 
Rapport
 5.88 
 24.11 
Kodiak
 0.17 
 12.11 
Xencor
 3.45 
 17.09 
Nurix
 6.60 
 50.54 
AnaptysBio
 0.46 
 19.70 
UroGen
 2.04 
 29.03 
Oculis
Market Volatility
(90 Days Market Risk)
Not too volatile
Somewhat reliable
Slightly risky
Not too volatile
Not too volatile
Not too volatile
Not too volatile
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Fair
Weak
Weak
Weak
Fair
Weakest
Good
Good
Weak
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Moderate
Risky
High
High
Low
Small
Low
Small
High
Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Hold
Strong Buy
Strong Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Current Ratio
N/A
9.93
N/A
N/A
8.65
7.81
5.26
22.79
7.74
N/A
Net Asset
396.02 M
378.32 M
194.42 M
314.93 M
335.58 M
951.95 M
688.13 M
483.83 M
285.71 M
120.35 M
Profit Margin
N/A
-1.87
N/A
N/A
N/A
-0.87
N/A
-0.5
-1.71
N/A
EBITDA
(82.23 M)
(261.52 M)
(80.66 M)
(77.47 M)
(149.5 M)
(186.17 M)
(244.84 M)
(92.74 M)
(95.35 M)
(72.8 M)
Current Valuation
1.36 B
1.13 B
856.64 M
773.78 M
1.54 B
482.28 M
1.27 B
1.09 B
969.79 M
1.45 B
Operating Margin
N/A
-0.31
N/A
N/A
N/A
-2.26
-6.12
0.45
-1.0
-83.52
Price To Book
N/A
25.37
N/A
2.48
58.65
1.41
3.15
114.73
19.27
9.54
Retained Earnings
(83.72 M)
(1.26 B)
(3.73 M)
(123.75 M)
(1.33 B)
(704.04 M)
(1 B)
(759.33 M)
(806.22 M)
(285.56 M)
Current Asset
N/A
N/A
N/A
N/A
7.31 M
97.67 M
N/A
297.84 M
N/A
N/A
Beta
N/A
0.49
N/A
N/A
2.67
0.97
1.94
0.32
1.36
0.14
Number Of Employees
28
427
81
69
123
250
317
136
287
49
Shares Outstanding
48.41 M
78.01 M
79.2 M
47.66 M
61.05 M
71.41 M
102.84 M
27.69 M
46.81 M
57.81 M
Cash Flow From Operations
(57.84 M)
(266.77 M)
(763.82 K)
(64.83 M)
(117.32 M)
(202.19 M)
(249.47 M)
(135.34 M)
(96.77 M)
(47.5 M)
Total Debt
968 K
554.95 M
5.71 M
1.48 M
70.34 M
231.95 M
55.73 M
369.46 M
123.39 M
1.18 M
Return On Equity
N/A
-34.89
N/A
-0.23
-2.08
-0.2
-0.5
-3.08
-14.81
-0.92
Number Of Shares Shorted
5.24 M
10.52 M
2.18 M
2.87 M
7.13 M
10.31 M
15.2 M
5.57 M
10.57 M
344.72 K
Book Value Per Share
10.0
-5.95
-403.34
10.74
0.45
8.77
5.29
-1.07
-2.47
3.26
Return On Asset
N/A
-0.43
N/A
-0.16
-0.47
-0.0909
-0.26
-0.0423
-0.34
-0.33
Current Liabilities
N/A
N/A
N/A
N/A
4.89 M
43.43 M
N/A
16.6 M
N/A
N/A
Total Asset
396.02 M
378.32 M
194.42 M
314.93 M
335.58 M
951.95 M
688.13 M
483.83 M
285.71 M
120.35 M
Short Ratio
7.52
8.04
2.07
6.95
6.39
12.56
9.97
10.53
13.93
2.06
Target Price
55.67
22.9
24.2
52.25
30.71
28.83
30.0
67.92
35.25
45.77
Debt To Equity
N/A
2.43
N/A
N/A
0.16
0.056
0.038
0.066
0.44
N/A
Shares Owned By Institutions
99.27
76.9
51.02
95.4
79.9
98.76
85.26
93.97
96.15
40.72
Market Capitalization
1.66 B
1.07 B
1.01 B
1.27 B
1.39 B
864.78 M
1.7 B
1.33 B
917.92 M
1.64 B
Price To Earning
N/A
N/A
N/A
N/A
-2.29
69.81
N/A
81.21
239.57
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.08
N/A
N/A
N/A
N/A
N/A
Price To Sales
N/A
7.25
N/A
N/A
N/A
5.76
20.23
7.83
9.51
2079.15
Net Income
(83.72 M)
(334.33 M)
7.6 M
(78.31 M)
(176.21 M)
(236.54 M)
(264.46 M)
(145.23 M)
(126.87 M)
(85.94 M)
Earnings Per Share
-0.59
-3.76
-1.11
-2.27
-4.12
-1.73
-3.05
-2.82
-3.47
-2.85
Shares Owned By Insiders
3.57
4.69
24.04
4.6
4.77
1.24
1.07
6.03
3.85
2.75
Revenue
N/A
55.25 M
N/A
N/A
N/A
110.49 M
83.98 M
91.28 M
90.4 M
686 K
Working Capital
363.83 M
274.41 M
139.11 M
301.04 M
146.36 M
490.17 M
520.35 M
386.45 M
230.19 M
60.66 M
Cash And Equivalents
N/A
207.39 M
N/A
N/A
597.88 M
511.92 M
344.48 M
442.15 M
111.74 M
N/A
Cash Per Share
N/A
5.39
N/A
N/A
11.55
8.57
7.31
15.66
4.91
N/A
Gross Profit
N/A
128.42 M
N/A
N/A
N/A
(75.53 M)
(232.92 M)
16.47 M
84.89 M
(54.77 M)
Day Typical Price
34.45
13.78
12.0
27.68
23.89
12.13
16.85
49.52
19.62
28.93
Accumulation Distribution
24600.06
21784.48
8756.59
10557.94
53431.37
26845.58
66973.38
42104.96
17130.7
9586.01
Market Facilitation Index
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Daily Balance Of Power
0.0372
0.25
0.4429
0.7917
0.7243
0.0351
0.4872
0.7964
0.12
0.6042
Period Momentum Indicator
0.07
0.14
0.31
1.14
1.34
0.02
0.57
3.13
0.09
0.58
Rate Of Daily Change
1.0
1.01
1.03
1.04
1.06
1.0
1.03
1.07
1.0
1.02
Day Median Price
34.52
13.77
11.98
27.65
23.78
12.14
16.74
49.02
19.59
28.88
Price Action Indicator
(0.19)
0.11
0.2
0.67
1.0
(0.01)
0.64
3.09
0.16
0.44
Relative Strength Index
58.32
46.08
49.29
50.12
48.93
39.42
49.5
59.62
46.37
79.6
Coefficient Of Variation
886.72
3778.89
4857.41
2757.64
1103.1
(1,530)
703.26
556.79
6618.5
377.92
Mean Deviation
2.88
2.74
3.41
2.72
4.17
2.77
3.2
2.72
3.24
1.82
Jensen Alpha
0.3899
0.0803
0.0912
0.1069
0.4031
(0.22)
0.6235
0.7171
0.0562
0.6879
Total Risk Alpha
0.187
(0.14)
(0.21)
(0.1)
0.1388
(0.46)
0.354
0.4406
(0.23)
0.5313
Sortino Ratio
0.1086
0.0112
0.0113
0.0182
0.0858
N/A
0.165
0.146
0.0038
0.3192
Downside Variance
12.6
14.1
13.82
13.96
24.19
N/A
12.92
18.92
17.6
4.18
Standard Deviation
3.91
3.7
4.75
3.41
5.27
3.51
4.56
3.85
4.74
2.68
Kurtosis
1.39
2.61
3.27
(0.12)
0.2428
0.0066
3.39
3.3
6.77
2.97
Potential Upside
6.36
5.99
8.45
5.18
10.04
6.33
9.23
6.44
6.25
5.79
Treynor Ratio
0.4769
0.5355
(1.18)
0.7478
0.3306
0.4696
1.9
(0.85)
0.5211
3.05
Maximum Drawdown
19.84
24.16
27.79
15.66
25.07
16.84
27.63
20.41
36.24
15.08
Variance
15.31
13.67
22.57
11.66
27.78
12.34
20.83
14.79
22.49
7.17
Market Risk Adjusted Performance
0.4869
0.5455
(1.17)
0.7578
0.3406
0.4796
1.91
(0.84)
0.5311
3.06
Risk Adjusted Performance
0.0908
0.0274
0.0235
0.0344
0.0751
(0.04)
0.1126
0.1397
0.0195
0.2012
Skewness
0.5183
(0.28)
1.23
(0.12)
0.1075
0.3677
1.15
(0.91)
1.03
1.21
Semi Deviation
3.19
3.68
3.65
3.58
4.44
N/A
3.09
3.7
4.07
1.3
Information Ratio
0.0985
0.0114
0.0089
0.0199
0.0801
(0.08)
0.13
0.1651
0.0034
0.2438
Value At Risk
(5.76)
(4.86)
(6.24)
(6.01)
(6.94)
(5.08)
(5.37)
(5.26)
(5.50)
(2.58)
Expected Short fall
(3.17)
(2.83)
(4.26)
(2.56)
(4.49)
N/A
(3.81)
(2.96)
(3.76)
(2.06)
Downside Deviation
3.55
3.75
3.72
3.74
4.92
N/A
3.59
4.35
4.2
2.04
Semi Variance
10.19
13.56
13.32
12.8
19.67
N/A
9.56
13.67
16.55
1.69

Oruka Therapeutics Competition Performance Charts

Five steps to successful analysis of Oruka Therapeutics Competition

Oruka Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Oruka Therapeutics in relation to its competition. Oruka Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Oruka Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Oruka Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Oruka Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Oruka Therapeutics position

In addition to having Oruka Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Growth Funds Thematic Idea Now

Small Growth Funds
Small Growth Funds Theme
Funds or Etfs that invest in stocks of small to mid-sized companies with above-average risk and growth rate that usually reinvest their earnings back into business. The Small Growth Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Growth Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Oruka Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oruka Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oruka Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oruka Therapeutics Stock:
How To Invest In Oruka
Details
Is Oruka Stock a good investment?
Details
What is Oruka Therapeutics' Net Worth?
Details
Top Sectors
View
Check out Oruka Therapeutics Correlation with its peers.
For information on how to trade Oruka Stock refer to our How to Trade Oruka Stock guide.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oruka Therapeutics. Anticipated expansion of Oruka directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Oruka Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Oruka Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Oruka Therapeutics' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Oruka Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Oruka Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oruka Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Oruka Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY